PATIENTS AND METHODS

Patient characteristics.
Between ianuary 1983 and October 1986, 578 patients from 28 institutions were included in this study.
Patients from 10 to 65 years of age were eligible whenever they had a newly diagnosed AML and met the following criteria: no previous treatment with chemotherapy or radiation therapy; no prior chamac- at the EORTC Data Center, using the institution as a stratification factor. The two randomized arms were as follows: 1. Arm A ("repeated" treatment):
DNR, 45 rng/m2 and VCR 1 mg/rn2 IV day 1; ana-C, 100 mg/rn2 subcutaneously every 12 hours, days I through 5. IV, on day 1, combined alternatingly with HD ara-C, 3 g/m2 in IV infusion oven one hour every I 2 hours on days 1 and 2 (four infusions), on with 5 azacytidine (AZA), 150 mg/rn2 IV over three hours on days 1, 2, and 3. AMSA was associated with HD ana-C on courses 1, 3, and 5, and with AZA on courses 2, 4, and 6. AZA was kindly supplied by the National
Cancer 
